Titan Medical Inc. Announces Exercised Warrants
TORONTO, ONTARIO -- (MARKET WIRE) -- 02/01/10 -- Titan Medical Inc. (TSX VENTURE: TMD) is pleased to announce that 3,220,786 of its total 9,014,498 warrants issued pursuant to its July 28, 2008 Going Public Event, were exercised by the January 28, 2010 expiry date. The warrants entitled holders to acquire one common share for $0.372. Total proceeds received as a result of warrants exercised was $1,198,132. Unexercised warrants of 5,793,712 expired.
As a result of the exercised and expired warrants, Titan's outstanding common shares and fully diluted common shares are as follows:
Outstanding common shares - 42,325,416
Fully diluted - 49,258,589
About Titan Medical Inc.
Titan Medical Inc. is focused on the development and commercialization of robotic surgical technologies. The Company is currently developing Amadeus®, a next generation 4-armed robotic surgical system, with the objective of enabling surgeons to remotely manipulate surgical instruments. Robotic surgery has developed over the past 10 years into a proven and growing method of treatment. The global robotic surgical market size is currently estimated to be $3.4 billion with potential for placement of 6,000 robotic surgical systems. The Company is researching and developing innovative technologies to empower surgeons to use robots in the operating room of the future.
Forward Looking Statements
This news release includes certain statements that may be deemed "forward-looking statements". All statements in this discussion other than statements of historical facts, that address future financings, acquisitions and events or developments that Titan expects, are forward-looking statements. Although Titan believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include the achievement of research and development milestones and objectives, market prices, regulatory approvals, continued availability of capital and financing and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Titan Medical Inc. Craig Leon Chief Executive Officer 416-548-7522 (ext. 151)
Released February 1, 2010